Pfizer’s Mylotarg has been approved by the English and Scottish NHS cost watchdogs as a restricted use treatment for a certain type of acute myeloid leukaemia (AML).
Eli Lilly’s Verzenio breast cancer drug has been approved in Europe, as the pharma prepares to compete with established rivals from Pfizer and Novartis.
Clovis Oncology’s Rubraca (rucaparib) has been designated as a Breakthrough Therapy by the FDA in prostate cancer, paving the way for a faster review if clinical trials work out.
High-profile digital health investor Luba Greenwood recently announced that she’s joined as Chair of the Board at Closed Loop Medicine, a company applying machine learning to precision drug